期刊
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.669363
关键词
JAK-STAT; STATs; hematopoiesis; hematopoietic stem cells; leukemia; STAT5
资金
- European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [813091]
- Cyprus Research and Innovation Promotion Foundation (RIF) [1216/0389_1]
Hematopoietic stem cells (HSCs) are regulated by both extracellular signals from the bone marrow niche and intrinsic cell signals, including the critical JAK-STAT pathway. Mutations in this pathway are associated with defects in HSCs and hematologic malignancies, making it a potential target for leukemia therapy. Therapeutic targeting of JAK-STAT shows promise in treating leukemia based on the role of this pathway in HSC regulation.
Hematopoietic stem cells (HSCs) produce all the terminally differentiated blood cells and are controlled by extracellular signals from the microenvironment, the bone marrow (BM) niche, as well as intrinsic cell signals. Intrinsic signals include the tightly controlled action of signaling pathways, as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Activation of JAK-STAT leads to phosphorylation of members of the STAT family to regulate proliferation, survival, and self-renewal of HSCs. Mutations in components of the JAK-STAT pathway are linked with defects in HSCs and hematologic malignancies. Accumulating mutations in HSCs and aging contribute to leukemia transformation. Here an overview of hematopoiesis, and the role of the JAK-STAT pathway in HSCs and in the promotion of leukemic transformation is presented. Therapeutic targeting of JAK-STAT and clinical implications of the existing research findings are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据